Compare Pharmacokinetics, Safety, and Immunogenicity of HLX11 vs. Perjeta in Healthy Chinese Male Subjects

Inclusion Criteria: * Healthy Chinese males * aged ≥ 18 and ≤ 45 * body mass index (BMI) ≥ 19 and ≤ 26 kg/m2 * LVEF≥ 55% Exclusion Criteria: * A history of any serious clinical disease such as haematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, mental, neurological diseases, and tumour, or allergic diseases * Use of a monoclonal antibody or any biological product within 6 months before study drug administration * A history of allergic reactions or anaphylaxis, including such reactions to any drug or excipient in the clinical study * Use of prescription drugs, over-the-counter drugs (OTC), or traditional Chinese medicine (TCM) (excluding vitamins, mineral supplements, and dietary supplements) within 28 days before study drug administration * A history of blood donation within 3 months before study drug administration * Participation in other clinical study and use of the investigational product/comparator within 3 months before study drug administration * Positive for hepatitis B surface antigen (HbsAg), hepatitis C virus (HCV) antibody, human immunodeficiency virus (HIV) antibody, or treponema pallidum antibody * A history of drug abuse * Failure to comply with protocol requirements, instructions, and study limitations, such as uncooperative attitude, failure to return to the study site for follow-up visits, or failure to complete the entire clinical study, as judged by investigators